Last reviewed · How we verify

NCT03537326: WADA

Study to Detect Oral Administration of Budesonide in Women.

Completed Phase 1 Last updated 11 September 2018
What this trial tests

Phase 1 trial testing Budesonide in Healthy in 4 participants. Completed in 10 September 2018.

Timeline
22 May 2018
Primary endpoint
1 July 2018
10 September 2018

Quick facts

Lead sponsorParc de Salut Mar
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposehealth services research
Enrollment4
Start date22 May 2018
Primary completion1 July 2018
Estimated completion10 September 2018
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Parc de Salut Mar — full company profile →

Who can join

Adults 18 to 45, female only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at identifying analysis strategies to detect oral administration of Budesonide in women; in order for them to be used by the accredited laboratories of the Worl Anti-Doping Agency (WADA).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Budesonide

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Parc de Salut Mar trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03537326.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing